Toyonaga Y, Kurosu Y, Kumagai K, Hori M
Jpn J Antibiot. 1980 Dec;33(12):1277-84.
The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis. This drug was administered to 2 pediatric patients with purulent meningitis at the dose to 50 mg/kg, by intravenous drip infusion over 30 minutes and one shot intravenous injection respectively. When spinal fluid levels were determined, about 15 approximately 30% of the drug concentration in blood was found to transfer to spinal fluid at acute stage. Spinal fluid levels were about 4 approximately 7 micrograms/ml. When 4 pediatric patients with purulent meningitis were treated with the drug, the good results were obtained in all of them. The dose given was 200 approximately 300 mg/kg/day and the dosing duration was 14 approximately 22 days. No adverse reaction was noted, nor abnormal laboratory test values were noted.
以下是对新型合成头孢菌素头孢呋辛在小儿化脓性脑膜炎患者中的基础和临床研究结果。该药物分别以50mg/kg的剂量通过30分钟静脉滴注和单次静脉注射给予2例小儿化脓性脑膜炎患者。测定脑脊液水平时，发现急性期血液中约15%至30%的药物浓度转移至脑脊液中。脑脊液水平约为4至7微克/毫升。当4例小儿化脓性脑膜炎患者接受该药物治疗时，所有患者均取得了良好效果。给药剂量为200至300mg/kg/天，给药持续时间为14至22天。未观察到不良反应，也未发现实验室检查值异常。
